当前位置: X-MOL 学术 › Microbiology Australia › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The challenges in commercialisation of Probiotic API manufacturing
Microbiology Australia Pub Date : 2020-05-19 , DOI: 10.1071/ma20021
Joe Liu , Brendan Cook , Shaun Roux

The concept of probiotics is well known and has developed into a high value commodity in recent times. Despite the ever-expanding number of probiotic products on our pharmacy, health food and supermarket shelves, the probiotic culture active ingredient has always been imported until now. In 2019, Probiotics Australia Pty Ltd opened Australia’s first and only Therapeutic Goods Administration/current Good Manufacturing Practice (TGA/cGMP) certified facility dedicated to the manufacture of probiotic active ingredients. This article outlines the significant export demand for Australian-made health products and the lengths to which Probiotics Australia have gone to create a facility to meet needs of the probiotics research, commercialisation and consumer market today and into the future.



中文翻译:

益生菌原料药生产的商业化挑战

益生菌的概念是众所周知的,近来已发展成为一种高价值的商品。尽管我们的药房,保健食品和超市货架上的益生菌产品数量不断增加,但迄今为止,益生菌培养活性成分一直是进口的。2019年,Probiotics Australia Pty Ltd开设了澳大利亚首家也是唯一一家经治疗药物管理局/现行药品生产质量管理规范(TGA / cGMP)认证的设施,专门生产益生菌活性成分。本文概述了对澳大利亚制造的保健产品的大量出口需求,以及澳大利亚益生菌公司为满足当今和未来益生菌研究,商业化和消费市场的需求而建立工厂所花费的时间。

更新日期:2020-05-19
down
wechat
bug